In the past, molecular pathways critically involved in the development of BCC and SCC, including EGFR/ERK and IGFR signalings, have been identified, leading to new pharmacological approaches for the treatment of these skin tumors [36, 37]. This evidence concerns the gene EGFR and skin neoplasm.